Company intelligence / Profile preview

PRCL Research

Montréal, Quebec, Canadamadrigalpharma.gcs-web.com ↗

Ownership: Private
Development stage: Preclinical

Overview

PRCL Research Inc. is a Canadian private biotech company established in 2013 to develop a single compound—PRCL-02, an oral CRAC channel inhibitor—for autoimmune diseases such as psoriasis. The company's business model centers on advancing this asset through human proof-of-concept studies with the backing of TVM Life Science Ventures VII and in partnership with Eli Lilly. Clinical trials have reached Phase 2 for moderate to severe chronic plaque psoriasis. If successful at proof-of-concept, Eli Lilly has an option to acquire the molecule.

Therapeutic areas: Dermatology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

PRCL-02

Partnerships

TVM Capital Life Science Ventures VIIEli Lilly and Company

Beyond the preview

Go deeper on PRCL Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRCL Research.

Explore the full profile